Overview:
Features national market profiles, market sizes and market forecasts to 2009
The veterinary vaccines sector accounted for 20% of global animal health product revenues in 2004. Global sales totalled $3.2 billion and the latest market forecasts predict the sector will grow in excess of $4 billion by 2009.
This report examines the market forces within this commercially important sector, highlighting key market drivers and providing a detailed analysis of future growth, enabling your organisation to:
- Understand the development and application of new technologies that have enabled the successful commercialisation of new vaccine types, including gene-deleted, subunit, naked DNA and vectored vaccines
- Identify the viral, bacterial and parasitic pathogens that represent core targets for veterinary vaccines in each of the main food and companion animal species
- Assess the world market for veterinary vaccines, charting recent growth and examining its structure by major market region and species.
- Examine trends in ownership, corporate restructuring and the rising costs associated with the development and commercialisation of new immunological technologies.
- Gather key information on the six leading veterinary vaccine companies, detailing the relative importance of vaccines as a revenue source and revealing related structural changes
Key findings
- Veterinary vaccine sales amounted to $3,205 million in 2004 and have risen by 7% per year since 2000. This figure is forecast to exceed $4 billion by 2009.
- The largest national markets are the US ($935 million), Japan ($236 million), France ($22 million) and Brazil ($221 million).
- The Brazilian vaccines market is dominated by FMD products, which account for 40% of sales. 348 million doses were sold in 2004.
- Six companies account for more than 70% of world veterinary vaccine sales. The market leader is Intervet, with sales of almost $600 million in 2004.
- More than half of Fort Dodges animal health sales are vaccines, and the company continues to invest in new products - a DNA vaccine against West Nile virus was approved by the USDA in July 2005, and the company has a five-year with the US government to develop an avian influenza vaccine antigen bank
- In France, sales of vaccines for small animals were worth ?50 million in 2004, accounting for 27% of total vaccine sales. The livestock and poultry markets are more valuable, but it is the small animal market that is driving growth.
View Cart
